The role of the microbiome in human health and disease: An introduction for clinicians

BMJ (Online)

Volumn 356, Issue , 2017, Pages

  Young, Vincent B ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; FIDAXOMICIN; PROBIOTIC AGENT;

ANTIBIOTIC THERAPY; BACTEREMIA; BACTERIOPHAGE; BIOLOGICAL THERAPY; CLOSTRIDIUM DIFFICILE INFECTION; CONCEPTUAL FRAMEWORK; DIET THERAPY; DISEASE ASSOCIATION; ENTERIC FEEDING; FECAL MICROBIOTA TRANSPLANTATION; HEALTH STATUS; HEPATIC ENCEPHALOPATHY; HOMEOSTASIS; HUMAN; INFLAMMATORY BOWEL DISEASE; LUNG DISEASE; MEDICAL RESEARCH; METABOLIC DISORDER; MICROBIAL COMMUNITY; MICROBIOME; MICROFLORA; NATIVE SPECIES; NONHUMAN; OBESITY; PROTEIN TARGETING; REVIEW; STRUCTURE ACTIVITY RELATION; ANIMAL; DISEASES; PHYSIOLOGY; PROCEDURES; THERAPY;

ANIMALS; BIOMEDICAL RESEARCH; DISEASE; HUMANS; MICROBIOTA; THERAPEUTICS;

EID: 85015783939     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.j831     Document Type: Review

References (153)

1. Johnson-King B, Terry SF. Future of microbiomes through the National Microbiome Initiative. Genet Test Mol Biomarkers 2016;20:561-2. doi:10.1089/gtmb.2016.29022.sjt.
2. Melber DJ, Teherani A, Schwartz BS. A comprehensive survey of preclinical microbiology curricula among US medical schools. Clin Infect Dis 2016;63:164-8. doi:10.1093/cid/ciw262.
3. Koch R. An address on bacteriological research. British Medical Journal1890;2(1546):380-3.
4. Gradmann C. A spirit of scientific rigour: Koch's postulates in twentieth-century medicine. Microbes Infect 2014;16:885-92. doi:10.1016/j. micinf.2014.08.012.
5. Gibbons SM, Gilbert JA. Microbial diversity-exploration of natural ecosystems and microbiomes. Curr Opin Genet Dev 2015;35:66-72. doi:10.1016/j.gde.2015.10.003.
6. Casadevall A, Pirofski LA. What is a host? Incorporating the microbiota into the damage-response framework. Infect Immun 2015;83:2-7. doi:10.1128/IAI.02627-14.
7. Li J, Jia H, Cai X, et al. An integrated catalog of reference genes in the human gut microbiome. Nat Biotechnol 2014;32:834-41. doi:10.1038/ nbt.2942.
8. Proctor LM. The National Institutes of Health Human Microbiome Project. Semin Fetal Neonatal Med 2016;21:368-72. doi:10.1016/j. siny.2016.05.002.
9. Marchesi JR, Ravel J. The vocabulary of microbiome research: a proposal. Microbiome 2015;3:31. doi:10.1186/s40168-015-0094-5.
10. Whipps JM, Lewis K, Cooke RC. Mycoparasitism and plant disease control. In: Burge MN, ed. Fungi in biological control systems. Manchester University Press, 1988:161-1887.
11. Tremaroli V, Backhed F. Functional interactions between the gut microbiota and host metabolism. Nature 2012;489:242-9. doi:10.1038/nature11552.
12. Manor O, Levy R, Borenstein E. Mapping the inner workings of the microbiome: genomic- and metagenomic-based study of metabolism and metabolic interactions in the human microbiome. Cell Metab 2014;20:742-52. doi:10.1016/j.cmet.2014.07.021.
13. Duffy LC, Raiten DJ, Hubbard VS, et al. Progress and challenges in developing metabolic footprints from diet in human gut microbial cometabolism. J Nutr 2015;145:1123S-30S. doi:10.3945/ jn.114.194936.
14. Hooper LV, Xu J, Falk PG, et al. A molecular sensor that allows a gut commensal to control its nutrient foundation in a competitive ecosystem. Proc Natl Acad Sci USA 1999;96:9833-8doi:10.1073/pnas.96.17.9833.
15. Cockburn DW, Koropatkin NM. Polysaccharide degradation by the intestinal microbiota and Its influence on human health and disease. J Mol Biol 2016;428:3230-52. doi:10.1016/j.jmb.2016.06.021.
16. Wong JM, de Souza R, Kendall CW, et al. Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol 2006;40:235-43doi:10.1097/00004836-200603000-00015.
17. Spanogiannopoulos P, Bess EN, Carmody RN, et al. The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism. Nat Rev Microbiol 2016;14:273-87. doi:10.1038/nrmicro.2016.17.
18. Haiser HJ, Gootenberg DB, Chatman K, et al. Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science 2013;341:295-8. doi:10.1126/science.1235872.
19. Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res 2006;47:241-59. doi:10.1194/jlr. R500013-JLR200.
20. Wahlstrom A, Sayin SI, Marschall HU, et al. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab 2016;24:41-50. doi:10.1016/j.cmet.2016.05.005.
21. Fiorucci S, Distrutti E. Bile acid-activated receptors, intestinal microbiota, and the treatment of metabolic disorders. Trends Mol Med 2015;21:702-14. doi:10.1016/j.molmed.2015.09.001.
22. Alawad AS, Levy C. FXR agonists: from bench to bedside, a guide for clinicians. Dig Dis Sci 2016;61:3395-404. doi:10.1007/s10620-016-4334-8.
23. Rooks MG, Garrett WS. Gut microbiota, metabolites and host immunity. Nat Rev Immunol 2016;16:341-52. doi:10.1038/nri.2016.42.
24. Olson GB, Wostmann BS. Lymphocytopoiesis, plasmacytopoiesis and cellular proliferation in nonantigenically stimulated germfree mice. J Immunol 1966;97:267-74.
25. Sefik E, Geva-Zatorsky N, Oh S, et al. Individual intestinal symbionts induce a distinct population of RORgamma(+) regulatory T cells. Science 2015;349:993-7. doi:10.1126/science.aaa9420.
26. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009;9:313-23. doi:10.1038/nri2515.
27. Schaedler RW, Dubs R, Costello R. Association of germfree mice with bacteria isolated from normal mice. J Exp Med 1965;122:77-82doi:10.1084/jem.122.1.77.
28. Stappenbeck TS, Hooper LV, Gordon JI. Developmental regulation of intestinal angiogenesis by indigenous microbes via Paneth cells. Proc Natl Acad Sci USA 2002;99:15451-5. doi:10.1073/pnas.202604299.
29. Hooper LV. Bacterial contributions to mammalian gut development. Trends Microbiol 2004;12:129-34doi:10.1016/j.tim.2004.01.001.
30. Bonder MJ, Kurilshikov A, Tigchelaar EF, et al. The effect of host genetics on the gut microbiome. Nat Genet 2016;48:1407-12. doi:10.1038/ng.3663.
31. Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 2015;350:1084-9. doi:10.1126/science.aac4255.
32. Vetizou M, Pitt JM, Daillere R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 2015;350:1079-84. doi:10.1126/science.aad1329.
33. Vollaard EJ, Clasener HA. Colonization resistance. Antimicrob Agents Chemother 1994;38:409-14doi:10.1128/AAC.38.3.409.
34. Lawley TD, Walker AW. Intestinal colonization resistance. Immunology 2013;138:1-11. doi:10.1111/j.1365-2567.2012.03616.x.
35. Bassis CM, Young VB, Schmidt TM. Methods for characterizing microbial communities associated with the human body. In: Fredricks DN, ed. The human microbiota: how microbial communities affect health and disease.Wiley, 2013: 51-74doi:10.1002/9781118409855.ch2.
36. Walker AW. Studying the human microbiota. Adv Exp Med Biol 2016;902:5-32. doi:10.1007/978-3-319-31248-4-2.
37. Di Bella JM, Bao Y, Gloor GB, et al. High throughput sequencing methods and analysis for microbiome research. J Microbiol Methods 2013;95:401-14. doi:10.1016/j.mimet.2013.08.011.
38. Allen-Vercoe E. Bringing the gut microbiota into focus through microbial culture: recent progress and future perspective. Curr Opin Microbiol 2013;16:625-9. doi:10.1016/j.mib.2013.09.008.
39. Lagier JC, Armougom F, Million M, et al. Microbial culturomics: paradigm shift in the human gut microbiome study. Clin Microbiol Infect 2012;18:1185-93. doi:10.1111/1469-0691.12023.
40. Sommer MO. Advancing gut microbiome research using cultivation. Curr Opin Microbiol 2015;27:127-32. doi:10.1016/j.mib.2015.08.004.
41. Schloss PD, Handelsman J. Status of the microbial census. Microbiol Mol Biol Rev 2004;68:686-91. doi:10.1128/MMBR.68.4.686-691.2004.
42. Pace NR, Stahl DA, Lane DJ, et al. Analyzing natural microbial populations by rRNA sequences. ASM News 1985;51:4-12.
43. Woese CR, Fox GE. Phylogenetic structure of the prokaryotic domain: the primary kingdoms. Proc Natl Acad Sci USA 1977;74:5088-90doi:10.1073/pnas.74.11.5088.
44. Frank DN, Pace NR. Gastrointestinal microbiology enters the metagenomics era. Curr Opin Gastroenterol 2008;24:4-10doi:10.1097/ MOG.0b013e3282f2b0e8.
45. Debelius J, Song SJ, Vazquez-Baeza Y, et al. Tiny microbes, enormous impacts: what matters in gut microbiome studies?Genome Biol 2016;17:217. doi:10.1186/s13059-016-1086-x.
46. Westcott SL, Schloss PD. De novo clustering methods outperform reference-based methods for assigning 16S rRNA gene sequences to operational taxonomic units. PeerJ 2015;3:e1487. doi:10.7717/peerj.1487.
47. Morgan XC, Huttenhower C. Meta'omic analytic techniques for studying the intestinal microbiome. Gastroenterology2014;146(6):1437-48 e1. doi:10.1053/j.gastro.2014.01.049
48. Faust K, Lahti L, Gonze D, et al. Metagenomics meets time series analysis: unraveling microbial community dynamics. Curr Opin Microbiol 2015;25:56-66. doi:10.1016/j.mib.2015.04.004.
49. Langille MG, Zaneveld J, Caporaso JG, et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat Biotechnol 2013;31:814-21. doi:10.1038/nbt.2676.
50. Handelsman J, Rondon MR, Brady SF, et al. Molecular biological access to the chemistry of unknown soil microbes: a new frontier for natural products. Chem Biol 1998;5:R245-9doi:10.1016/S1074-5521(98)90108-9.
51. Streit WR, Schmitz RA. Metagenomics-the key to the uncultured microbes. Curr Opin Microbiol 2004;7:492-8doi:10.1016/j. mib.2004.08.002.
52. Verberkmoes NC, Russell AL, Shah M, et al. Shotgun metaproteomics of the human distal gut microbiota. ISME J 2009;3:179-89. doi:10.1038/ ismej.2008.108.
53. Bjerrum JT, Wang Y, Hao F, et al. Metabonomics of human fecal extracts characterize ulcerative colitis, Crohn's disease and healthy individuals. Metabolomics 2015;11:122-33. doi:10.1007/s11306-014-0677-3.
54. Turnbaugh PJ, Ley RE, Hamady M, et al. The human microbiome project. Nature 2007;449:804-10. doi:10.1038/nature06244.
55. Proctor LM. The Human Microbiome Project in 2011 and beyond. Cell Host Microbe 2011;10:287-91. doi:10.1016/j.chom.2011.10.001.
56. Gevers D, Knight R, Petrosino JF, et al. The Human Microbiome Project: a community resource for the healthy human microbiome. PLoS Biol 2012;10:e1001377. doi:10.1371/journal.pbio.1001377.
57. Human Microbiome Project. Structure, function and diversity of the healthy human microbiome. Nature 2012;486:207-14. doi:10.1038/ nature11234.
58. Theriot CM, Koenigsknecht MJ, Carlson PE Jr, et al. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat Commun 2014;5:3114. doi:10.1038/ncomms4114.
59. Frank DN, St Amand AL, Feldman RA, et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 2007;104:13780-5. doi:10.1073/pnas.0706625104.
60. Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe 2014;15:382-92. doi:10.1016/j.chom.2014.02.005.
61. Kemppainen KM, Ardissone AN, Davis-Richardson AG, et al. Early childhood gut microbiomes show strong geographic differences among subjects at high risk for type 1 diabetes. Diabetes Care 2015;38:329-32. doi:10.2337/dc14-0850.
62. Young VB, Raffals LH, Huse SM, et al. Multiphasic analysis of the temporal development of the distal gut microbiota in patients following ileal pouch anal anastomosis. Microbiome 2013;1:9. doi:10.1186/2049-2618-1-9.
63. Morgan XC, Tickle TL, Sokol H, et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 2012;13:R79. doi:10.1186/gb-2012-13-9-r79.
64. Bartlett JG, Onderdonk AB, Cisneros RL, et al. Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J Infect Dis 1977;136:701-5doi:10.1093/infdis/136.5.701.
65. Bartlett JG, Chang TW, Gurwith M, et al. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med 1978;298:531-4doi:10.1056/NEJM197803092981003.
66. Weingarden AR, Chen C, Bobr A, et al. Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am J Physiol Gastrointest Liver Physiol 2014;306:G310-9. doi:10.1152/ajpgi.00282.2013.
67. Theriot CM, Bowman AA, Young VB. Antibiotic-induced alterations of the gut microbiota alter secondary bile acid production and allow for clostridium difficile spore germination and outgrowth in the large intestine. mSphere2016;1(1) doi:10.1128/mSphere.00045-15
68. Wilson KH. Efficiency of various bile salt preparations for stimulation of Clostridium difficile spore germination. J Clin Microbiol 1983;18:1017-9.
69. Sorg JA, Sonenshein AL. Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid. J Bacteriol 2010;192:4983-90. doi:10.1128/JB.00610-10.
70. Rao K, Young VB. Fecal microbiota transplantation for the management of Clostridium difficile infection. Infect Dis Clin North Am 2015;29:109-22. doi:10.1016/j.idc.2014.11.009.
71. Brandl K, Plitas G, Mihu CN, et al. Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits. Nature 2008;455:804-7. doi:10.1038/nature07250.
72. Ubeda C, Taur Y, Jenq RR, et al. Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. J Clin Invest 2010;120:4332-41doi:10.1172/JCI43918.
73. Taur Y, Xavier JB, Lipuma L, et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2012;55:905-14. doi:10.1093/cid/ cis580.
74. Dickson R P, Singer BH, Newstead MW, et al. Enrichment of the lung microbiome with gut bacteria in sepsis and the acute respiratory distress syndrome. New Microbiol 2016;1:16113. doi:10.1038/ nmicrobiol.2016.113.
75. Shogan BD, Smith D P, Christley S, et al. Intestinal anastomotic injury alters spatially defined microbiome composition and function. Microbiome 2014;2:35. doi:10.1186/2049-2618-2-35.
76. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008;134:577-94doi:10.1053/j. gastro.2007.11.059.
77. Peterson DA, Frank DN, Pace NR, et al. Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases. Cell Host Microbe 2008;3:417-27doi:10.1016/j.chom.2008.05.001.
78. Li E, Hamm CM, Gulati AS, et al. Inflammatory bowel diseases phenotype, C. difficile and NOD2 genotype are associated with shifts in human ileum associated microbial composition. PLoS One 2012;7:e26284. doi:10.1371/journal.pone.0026284.
79. Swidsinski A, Weber J, Loening-Baucke V, et al. Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol 2005;43:3380-9doi:10.1128/JCM.43.7.3380-3389.2005.
80. Morgan XC, Kabakchiev B, Waldron L, et al. Associations between host gene expression, the mucosal microbiome, and clinical outcome in the pelvic pouch of patients with inflammatory bowel disease. Genome Biol 2015;16:67. doi:10.1186/s13059-015-0637-x.
81. Huttenhower C, Kostic AD, Xavier RJ. Inflammatory bowel disease as a model for translating the microbiome. Immunity 2014;40:843-54. doi:10.1016/j.immuni.2014.05.013.
82. Gkouskou KK, Deligianni C, Tsatsanis C, et al. The gut microbiota in mouse models of inflammatory bowel disease. Front Cell Infect Microbiol 2014;4:28. doi:10.3389/fcimb.2014.00028.
83. Wirtz S, Neurath MF. Mouse models of inflammatory bowel disease. Adv Drug Deliv Rev 2007;59:1073-83doi:10.1016/j.addr.2007.07.003.
84. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-6doi:10.1038/35079114.
85. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603doi:10.1038/35079107.
86. Ley RE, Turnbaugh PJ, Klein S, et al. Microbial ecology: human gut microbes associated with obesity. Nature 2006;444:1022-3doi:10.10 38/4441022a.
87. Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006;444:1027-31doi:10.1038/nature05414.
88. Rajala MW, Patterson CM, Opp JS, et al. Leptin acts independently of food intake to modulate gut microbial composition in male mice. Endocrinology 2014;155:748-57. doi:10.1210/en.2013-1085.
89. Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature 2009;457:480-4. doi:10.1038/ nature07540.
90. Jumpertz R, Le DS, Turnbaugh PJ, et al. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am J Clin Nutr 2011;94:58-65. doi:10.3945/ ajcn.110.010132.
91. Sze MA, Schloss PD. Looking for a signal in the noise: revisiting obesity and the microbiome. MBio 2016;7. doi:10.1128/mBio.01018-16.
92. Greiner TU, Backhed F. Microbial regulation of GLP-1 and L-cell biology. Mol Metab 2016;5:753-8. doi:10.1016/j.molmet.2016.05.012.
93. Trabelsi MS, Daoudi M, Prawitt J, et al. Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. Nat Commun 2015;6:7629. doi:10.1038/ncomms8629.
94. Parseus A, Sommer N, Sommer F, et al. Microbiota-induced obesity requires farnesoid X receptor. Gut 2016.
95. Ussar S, Griffin NW, Bezy O, et al. Interactions between gut microbiota, host genetics and diet modulate the predisposition to obesity and metabolic syndrome. Cell Metab 2015;22:516-30. doi:10.1016/j. cmet.2015.07.007.
96. Cho I, Yamanishi S, Cox L, et al. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature 2012;488:621-6. doi:10.1038/nature11400.
97. Livanos AE, Greiner TU, Vangay P, et al. Antibiotic-mediated gut microbiome perturbation accelerates development of type 1 diabetes in mice. New Microbiol 2016;1:16140. doi:10.1038/nmicrobiol.2016.140.
98. Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011;472:57-63. doi:10.1038/nature09922.
99. Bassis CM, Erb-Downward JR, Dickson RP, et al. Analysis of the upper respiratory tract microbiotas as the source of the lung and gastric microbiotas in healthy individuals. MBio 2015;6. doi:10.1128/ mBio.00037-15.
100. Venkataraman A, Bassis CM, Beck JM, et al. Application of a neutral community model to assess structuring of the human lung microbiome. MBio 2015;6. doi:10.1128/mBio.02284-14.
101. Charlson ES, Bittinger K, Haas AR, et al. Topographical continuity of bacterial populations in the healthy human respiratory tract. Am J Respir Crit Care Med 2011;184:957-63. doi:10.1164/rccm.201104-0655OC.
102. Segal LN, Clemente JC, Tsay JC, et al. Enrichment of the lung microbiome with oral taxa is associated with lung inflammation of a Th17 phenotype. New Microbiol 2016;1:16031. doi:10.1038/nmicrobiol.2016.31.
103. Huang YJ. LiPuma JJ. The microbiome in cystic fibrosis. Clin Chest Med 2016;37:59-67. doi:10.1016/j.ccm.2015.10.003.
104. Carmody LA, Zhao J, Schloss PD, et al. Changes in cystic fibrosis airway microbiota at pulmonary exacerbation. Ann Am Thorac Soc 2013;10:179-87. doi:10.1513/AnnalsATS.201211-107OC.
105. Zhao J, Schloss PD, Kalikin LM, et al. Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci USA 2012;109:5809-14. doi:10.1073/pnas.1120577109.
106. Flynn JM, Niccum D, Dunitz JM, et al. Evidence and role for bacterial mucin degradation in cystic fibrosis airway disease. PLoS Pathog 2016;12:e1005846. doi:10.1371/journal.ppat.1005846.
107. Huang YJ, Erb-Downward JR, Dickson RP, et al. Understanding the role of the microbiome in chronic obstructive pulmonary disease: principles, challenges, and future directions. Transl Res 2017;179:71-83. doi:10.1016/j.trsl.2016.06.007.
108. Sze MA, Morris A. Launching into the deep: does the pulmonary microbiota promote chronic lung inflammation and chronic obstructive pulmonary disease pathogenesis?Am J Respir Crit Care Med 2016;193:938-40. doi:10.1164/rccm.201512-2329ED.
109. Huang YJ, Nariya S, Harris JM, et al. The airway microbiome in patients with severe asthma: associations with disease features and severity. J Allergy Clin Immunol 2015;136:874-84. doi:10.1016/j. jaci.2015.05.044.
110. Huang YJ, Boushey HA. The sputum microbiome in chronic obstructive pulmonary disease exacerbations. Ann Am Thorac Soc 2015;12(Suppl 2):S176-80. doi:10.1513/AnnalsATS.201506-319AW.
111. Yadava K, Pattaroni C, Sichelstiel AK, et al. Microbiota promotes chronic pulmonary inflammation by enhancing IL-17A and autoantibodies. Am J Respir Crit Care Med 2016;193:975-87. doi:10.1164/rccm.201504-0779OC.
112. Anderson M, Stokken J, Sanford T, et al. A systematic review of the sinonasal microbiome in chronic rhinosinusitis. Am J Rhinol Allergy 2016;30:161-6. doi:10.2500/ajra.2016.30.4320.
113. Abreu NA, Nagalingam NA, Song Y, et al. Sinus microbiome diversity depletion and Corynebacterium tuberculostearicum enrichment mediates rhinosinusitis. Sci Transl Med 2012;4:151ra24. doi:10.1126/ scitranslmed.3003783.
114. Cope EK, Goldberg AN, Pletcher SD, et al. A chronic rhinosinusitis-derived isolate of Pseudomonas aeruginosa induces acute and pervasive effects on the murine upper airway microbiome and host immune response. Int Forum Allergy Rhinol 2016;6:1229-37. doi:10.1002/alr.21819.
115. Schenck LP, Surette MG, Bowdish DM. Composition and immunological significance of the upper respiratory tract microbiota. FEBS Lett 2016;590:3705-20. doi:10.1002/1873-3468.12455.
116. Hofstra JJ, Matamoros S, van de Pol MA, et al. Changes in microbiota during experimental human Rhinovirus infection. BMC Infect Dis 2015;15:336. doi:10.1186/s12879-015-1081-y.
117. Bajaj JS. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis. Aliment Pharmacol Ther 2016;43(Suppl 1):11-26. doi:10.1111/apt.13435.
118. Li J, Zhu W, Liu W, et al. Rifaximin for irritable bowel syndrome: a meta-analysis of randomized placebo-controlled trials. Medicine (Baltimore) 2016;95:e2534. doi:10.1097/MD.0000000000002534.
119. Perencevich M, Burakoff R. Use of antibiotics in the treatment of inflammatory bowel disease. Inflamm Bowel Dis 2006;12:651-64doi:10.1097/01.MIB.0000225330.38119.c7.
120. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011;364:422-31. doi:10.1056/NEJMoa0910812.
121. Langdon A, Crook N, Dantas G. The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. Genome Med 2016;8:39. doi:10.1186/ s13073-016-0294-z.
122. Pettigrew MM, Johnson JK, Harris AD. The human microbiota: novel targets for hospital-acquired infections and antibiotic resistance. Ann Epidemiol 2016;26:342-7. doi:10.1016/j.annepidem.2016.02.007.
123. Nobrega FL, Costa AR, Kluskens LD, et al. Revisiting phage therapy: new applications for old resources. Trends Microbiol 2015;23:185-91. doi:10.1016/j.tim.2015.01.006.
124. Orndorff PE. Use of bacteriophage to target bacterial surface structures required for virulence: a systematic search for antibiotic alternatives. Curr Genet 2016;62:753-7. doi:10.1007/s00294-016-0603-5.
125. Vandenheuvel D, Lavigne R, Brussow H. Bacteriophage therapy: advances in formulation strategies and human clinical trials. Annu Rev Virol 2015;2:599-618. doi:10.1146/annurev-virology-100114-054915.
126. Reid G. Probiotics: definition, scope and mechanisms of action. Best Pract Res Clin Gastroenterol 2016;30:17-25. doi:10.1016/j. bpg.2015.12.001.
127. Kaufmann SH. Elie Metchnikoff's and Paul Ehrlich's impact on infection biology. Microbes Infect 2008;10:1417-9doi:10.1016/j. micinf.2008.08.012.
128. Sanders ME. Probiotics: definition, sources, selection, and uses. Clin Infect Dis2008;46(Suppl 2):S58-61; discussion S144-51. doi:10.1086/523341
129. Goldenberg JZ, Lytvyn L, Steurich J, et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2015;(12):CD004827. doi:10.1002/14651858.CD004827.pub4.
130. Schnadower D, Finkelstein Y, Freedman SB. Ondansetron and probiotics in the management of pediatric acute gastroenteritis in developed countries. Curr Opin Gastroenterol 2015;31:1-6. doi:10.1097/ MOG.0000000000000132.
131. Ollech JE, Shen NT, Crawford CV, et al. Use of probiotics in prevention and treatment of patients with Clostridium difficile infection. Best Pract Res Clin Gastroenterol 2016;30:111-8. doi:10.1016/j.bpg.2016.01.002.
132. Allen SJ, Wareham K, Wang D, et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2013;382:1249-57. doi:10.1016/S0140-6736(13)61218-0.
133. Howerton A, Patra M, Abel-Santos E. A new strategy for the prevention of Clostridium difficile infections. J Infect Dis 2013;207:1498-504. doi:10.1093/infdis/jit068.
134. Koropatkin NM, Cameron EA, Martens EC. How glycan metabolism shapes the human gut microbiota. Nat Rev Microbiol 2012;10:323-35. doi:10.1038/nrmicro2746.
135. Louis P, Flint HJ, Michel C. How to manipulate the microbiota: prebiotics. Adv Exp Med Biol 2016;902:119-42. doi:10.1007/978-3-319-31248-4-9.
136. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 1995;125:1401-12.
137. Quince C, Ijaz UZ, Loman N, et al Extensive modulation of the fecal metagenome in children with Crohn's disease during exclusive enteral nutrition. Am J Gastroenterol2015;110(12):1718-29; quiz 30. doi:10.1038/ajg.2015.357
138. Lee D, Baldassano RN, Otley AR, et al. Comparative effectiveness of nutritional and biological therapy in north american children with active crohn's disease. Inflamm Bowel Dis 2015;21:1786-93. doi:10.1097/ MIB.0000000000000426.
139. Fuentes S, de Vos WM. How to manipulate the microbiota: fecal microbiota transplantation. Adv Exp Med Biol 2016;902:143-53. doi:10.1007/978-3-319-31248-4-10.
140. Brandt LJ. Fecal microbiota transplant: respice, adspice, prospice. J Clin Gastroenterol 2015;49(Suppl 1):S65-8. doi:10.1097/ MCG.0000000000000346.
141. Rao K, Young VB. Fecal microbiota transplantation for the management of Clostridium difficile infection. Infect Dis Clin North Am 2015;29:109-22. doi:10.1016/j.idc.2014.11.009.
142. Zhang F, Luo W, Shi Y, et al Should we standardize the 1,700-year-old fecal microbiota transplantation? The American journal of gastroenterology2012;107(11):1755; author reply p 55-6. doi:10.1038/ajg.2012.251
143. Rao K, Safdar N. Fecal microbiota transplantation for the treatment of Clostridium difficile infection. J Hosp Med 2016;11:56-61. doi:10.1002/ jhm.2449.
144. Eiseman B, Silen W, Bascom GS, et al. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958;44:854-9.
145. Khanna S, Pardi DS, Kelly CR, et al. A novel microbiome therapeutic increases gut microbial diversity and prevents recurrent Clostridium difficile infection. J Infect Dis 2016;214:173-81. doi:10.1093/infdis/ jiv766.
146. Youngster I, Russell GH, Pindar C, et al. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA 2014;312:1772-8. doi:10.1001/jama.2014.13875.
147. Orenstein R, Dubberke E, Hardi R, et al. Safety and durability of RBX2660 (microbiota suspension) for recurrent Clostridium difficile infection: results of the PUNCH CD study. Clin Infect Dis 2016;62:596-602. doi:10.1093/cid/civ938.
148. Furuya-Kanamori L, Doi SA, Paterson DL, et al. Upper versus lower gastrointestinal delivery for transplantation of fecal microbiota in recurrent or refractory Clostridium difficile infection: a collaborative analysis of individual patient data from 14 studies. J Clin Gastroenterol 2016. doi:10.1097/MCG.0000000000000511.
149. Kelly CR, Khoruts A, Staley C, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trials. Ann Intern Med 2016;165:609-16. doi:10.7326/M16-0271.
150. Scaldaferri F, Pecere S, Petito V, et al. Efficacy and mechanisms of action of fecal microbiota transplantation in ulcerative colitis: pitfalls and promises from a first meta-analysis. Transplant Proc 2016;48:402-7. doi:10.1016/j.transproceed.2015.12.040.
151. Kahn SA, Rubin DT. When subjects violate the research covenant: lessons learned from a failed clinical trial of fecal microbiota transplantation. Am J Gastroenterol 2016;111:1508-10. doi:10.1038/ajg.2016.153.
152. Young VB. Therapeutic manipulation of the microbiota: past, present and considerations for the future. Clin Microbiol Infect 2016;22:905-9. doi:10.1016/j.cmi.2016.09.001.
153. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med 2015;372:793-5. doi:10.1056/NEJMp1500523.